{"version":"1.0","provider_name":"The Medical Xchange","provider_url":"https:\/\/themedicalxchange.com\/en\/","title":"Expansion in Biologic Option Critical For Non-Responders to TNF Inhibitors - The Medical Xchange","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"PGy5DnphuU\"><a href=\"https:\/\/themedicalxchange.com\/en\/2015\/11\/19\/american-college-of-rheumatology-acr-2015-congress\/\">Expansion in Biologic Option Critical For Non-Responders to TNF Inhibitors<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/themedicalxchange.com\/en\/2015\/11\/19\/american-college-of-rheumatology-acr-2015-congress\/embed\/#?secret=PGy5DnphuU\" width=\"600\" height=\"338\" title=\"&#8220;Expansion in Biologic Option Critical For Non-Responders to TNF Inhibitors&#8221; &#8212; The Medical Xchange\" data-secret=\"PGy5DnphuU\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/themedicalxchange.com\/wp-includes\/js\/wp-embed.min.js\n\/* ]]> *\/\n<\/script>\n","thumbnail_url":"https:\/\/themedicalxchange.com\/wp-content\/uploads\/2015\/11\/2355_ACR_slides_Fig_1.PNG","thumbnail_width":960,"thumbnail_height":720,"description":"San Francisco \u2013 Evidence that newer biologics are effective for restoring benefit in patients with rheumatoid arthritis (RA) who have lost response to an initial targeted therapy has been expanded by new data presented at the 2015 ACR Congress. Despite the major contribution made by tumor necrosis factor (TNF) inhibitors\u2014and subsequently by other biologics\u2014to the control of moderate to severe RA, new options are needed when initial therapy fails. Data presented here confirm that newer investigational biologics provide high levels of response in patients who have progressed on a previous biologic."}